SCHEMBL24399714

SCHEMBL24399714

Cc1ccc2c(Nc3cc(F)c(F)cc3F)nccc2c1N

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.36
BRAF P15056 6/20 0.35
RAF1 P04049 5/20 0.35
CSF1R P07333 2/20 0.35
DDR1 Q08345 2/20 0.35
DDR2 Q16832 2/20 0.35
ARAF P10398 1/20 0.35
KDR P35968 3/20 0.34
RET P07949 2/20 0.34
KIF5B P33176 2/20 0.34
FGFR1 P11362 1/20 0.34
FLT1 P17948 1/20 0.34
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
LCK P06239 1/20 0.33
NOS3 P29474 1/20 0.33
NOS2 P35228 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29638638 1.00 EGFR (0.36) EGFRBRAFRAF1CSF1RDDR1
SCHEMBL24399762 0.87 DHFR (0.40) EGFRBRAFRAF1CSF1RDDR1
SCHEMBL26210494 0.87 HDAC3 (0.44) EGFRBRAFRAF1CSF1RKDR
SCHEMBL24399688 0.87 FGFR1 (0.44) BRAFRAF1KDRFGFR1FLT1
SCHEMBL29638582 0.87 BRAF (0.35) EGFRBRAFRAF1CSF1RDDR1
SCHEMBL26210990 0.87 BRAF (0.35) EGFRBRAFRAF1CSF1RDDR1
SCHEMBL24399614 0.86 ADORA2A (0.46) EGFRBRAFRAF1CSF1RDDR1
SCHEMBL26207944 0.85 KDR (0.46) EGFRBRAFRAF1CSF1RDDR1
SCHEMBL26210662 0.85 EGFR (0.45) EGFRBRAFRAF1CSF1RDDR1
SCHEMBL29638567 0.84 BRAF (0.36) BRAFRAF1CSF1RDDR1DDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 US disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 EP disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 EP disclosed
WO-2022089219-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF AHR, ARNT, NOTUM EGFR 844/4885BRAF 720/4885RAF1 2075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.